Minerva Neurosciences Inc/$NERV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Ticker
$NERV
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
8
Website
NERV Metrics
BasicAdvanced
$13M
2.26
$0.83
-0.39
-
Price and volume
Market cap
$13M
Beta
-0.39
52-week high
$2.31
52-week low
$1.15
Average daily volume
16K
Financial strength
Current ratio
9.206
Quick ratio
8.88
Long term debt to equity
-205.839
Total debt to equity
-205.839
Interest coverage (TTM)
-8.25%
Profitability
EBITDA (TTM)
-19.064
Management effectiveness
Return on assets (TTM)
-28.61%
Return on equity (TTM)
-19.03%
Valuation
Price to earnings (TTM)
2.264
Price to book
-0.45
Price to tangible book (TTM)
-0.3
Price to free cash flow (TTM)
-0.807
Free cash flow yield (TTM)
-123.84%
Free cash flow per share (TTM)
-2.316
Growth
Earnings per share change (TTM)
-118.46%
3-year earnings per share growth (CAGR)
-55.74%
10-year earnings per share growth (CAGR)
-30.25%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Minerva Neurosciences Inc stock?
Minerva Neurosciences Inc (NERV) has a market cap of $13M as of August 01, 2025.
What is the P/E ratio for Minerva Neurosciences Inc stock?
The price to earnings (P/E) ratio for Minerva Neurosciences Inc (NERV) stock is 2.26 as of August 01, 2025.
Does Minerva Neurosciences Inc stock pay dividends?
No, Minerva Neurosciences Inc (NERV) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Minerva Neurosciences Inc dividend payment date?
Minerva Neurosciences Inc (NERV) stock does not pay dividends to its shareholders.
What is the beta indicator for Minerva Neurosciences Inc?
Minerva Neurosciences Inc (NERV) has a beta rating of -0.39. This means that it has an inverse relation to market volatility.